Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Increased plasma DOPA decarboxylase levels in Lewy body disorders are driven by dopaminergic treatment.
Nat Commun
January 2025
Neurochemistry Laboratory, Department of Laboratory Medicine, Amsterdam Neuroscience, VU University Medical Center, Amsterdam UMC, Amsterdam, The Netherlands.
DOPA Decarboxylase (DDC) has been proposed as a cerebrospinal fluid (CSF) biomarker with increased concentrations in Lewy body disorders (LBDs) and highest levels in patients receiving dopaminergic treatment. Here we evaluate plasma DDC, measured by proximity extension assay, and the effect of dopaminergic treatment in three independent LBD (with a focus on dementia with Lewy bodies (DLB) and Parkinson's disease (PD)) cohorts: an autopsy-confirmed cohort (n = 71), a large multicenter, cross-dementia cohort (n = 1498) and a longitudinal cohort with detailed treatment information (n = 66, median follow-up time[IQR] = 4[4, 4] years). Plasma DDC was not altered between different LBDs and other disease groups or controls in absence of treatment.
View Article and Find Full Text PDFAcute appendicitis and its treatment: a historical overview.
Int J Colorectal Dis
January 2025
Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, Rende, Italy.
Purpose: Acute appendicitis (AA) is the leading cause of acute abdomen worldwide, with an incidence of 90-100 cases per 100,000 individuals annually and a lifetime risk of 7-12%. Despite its prevalence, historical accounts of AA are limited, particularly when compared to conditions like haemorrhoids, likely due to the appendix's internal location. This article traces the historical evolution of AA treatment from ancient times to the present, highlighting key contributions.
View Article and Find Full Text PDF12th Brazilian Congress of Epidemiology: innovative solutions for contemporary health challenges.
Cad Saude Publica
January 2025
Universidade Estadual de Feira de Santana, Feira de Santana, Brasil.
Developing a global education hub for animal-free innovation.
ALTEX
January 2025
Universitat de Barcelona, Dept Biochemistry and Physiology, Barcelona, Spain.
Multiplex basophil activation tests for allergy diagnosis: present and future applications.
Front Allergy
January 2025
Laboratory for Clinical Immunology and Molecular Genetics, University Clinic of Respiratory and Allergic Diseases Golnik, Golnik, Slovenia.
The basophil activation test (BAT) has become a major cellular test for evaluating the allergenic activity of specific IgEs. The impact of the BAT is due to the ability of blood basophil granulocytes to present IgE on the high-affinity FcRI receptor and to mirror the mast cell response that elicits an acute allergic reaction. The BAT proved to be able to identify allergic patients at risk of reacting to a low dose of the allergen and/or developing life-threatening reactions and thus can significantly improve the current management of allergic patients.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!